Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

FDA Approves First New Molecular Entity Under National Priority Voucher Program

 April 1, 2026

FDA

The U.S.

RegulatoryRead full story

Post navigation

Ambrosia adds a megaround for obesity drugs →
← Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com